SAN DIEGO & MADRID, Spain--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX) (FWB:XMPA) and Hospital Gregorio Marañón in Madrid, Spain treated the first patient in Cytori’s randomized clinical trial investigating the safety and feasibility of adipose-derived stem and regenerative cells as a therapy for cardiovascular disease.
